Web2013 when pharmaceutical giant Roche announced a partnership with Ionis to develop the ASO drug for HD, which they call *IONIS-HTT Rx *. This brought huge resources and experience at Roche to bear on the problem of Huntington’s disease. In July 2015, the most exciting drug trial so far in Huntington’s disease began - one in which an WebOct 11, 2024 · Ionis Pharmaceuticals has entered a deal worth up to $760m with Roche for further development of its antisense drug, IONIS-FB-L, to treat complement-mediated diseases. IONIS-FB-L is designed using Ionis’ antisense technology platform. It uses the company’s ligand conjugated antisense (LICA) technology to decrease the generation of …
Ionis
WebMar 23, 2024 · The pharmaceutical company Roche announced yesterday that it had stopped giving patients doses of the antisense drug tominersen in the pivotal clinical trial … WebMay 5, 2024 · “The Roche trial in particular left the community quite devastated,” says Cath Stanley, chief executive of the Huntington’s Disease Association, a UK advocacy group supporting people with... the porcelain factory
Roche Suspends Early-Stage Huntington
WebMar 23, 2024 · Ionis plunges after partner Roche says it will discontinue dosing in its Phase 3 study of tominersen in manifest Huntington's disease. The company said in a statement that the decision was based ... WebMar 22, 2024 · ZURICH (Reuters) - Roche is calling it quits on a late-stage trial of its Huntington's disease hopeful tominersen, the Swiss drugmaker said on Monday, a blow … WebDear members of the Huntington’s community, Today is an exciting day for the Huntington’s disease community. The Phase 1/2a Study of IONIS-HTT Rx, the first therapy in clinical … the porcelain needle etsy